-
First-trimester maternal factors and biomarker screening for preeclampsia.
Poon LC, Nicolaides KH.
Prenat Diagn 2014;34:618-27. pdf -
Low-dose aspirin for prevention of adverse outcomes related to abnormal placentation.
Bujold E, Roberge S, Nicolaides KH.
Prenat Diagn 2014;34:642-8. pdf -
First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing.
Wright D, Syngelaki A, Bradbury I, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2014;35:118-26. pdf -
Maternal age and adverse pregnancy outcomes: a cohort study.
Khalil A, Syngelaki A, Maiz N, Zinevich Y, Nicolaides KH.
Ultrasound Obstet Gynecol 2013;42:634-43. pdf -
Combined screening for preeclampsia and small for gestational age at 11-13 weeks.
Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH.
Fetal Diagn Ther 2013;33:16-27. -
Maternal Serum Placental Growth Factor, Pregnancy-Associated Plasma Protein-A and Free β-Human Chorionic Gonadotrophin at 30-33 Weeks in the Prediction of Pre-Eclampsia.
Lai J, Pinas A, Poon LC, Agathokleous M, Nicolaides KH.
Fetal Diagn Ther 2013;33:164-72. -
Maternal racial origin and adverse pregnancy outcome: a cohort study.
Khalil A, Rezende J, Akolekar R, Syngelaki A, Nicolaides KH.
Ultrasound Obstet Gynecol 2013;41:278-85. -
Competing risks model in early screening for preeclampsia by biophysical and biochemical markers.
Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH.
Fetal Diagn Ther 2013;33:8-15. -
Quantitative ELISAs for serum soluble LHCGR and hCG-LHCGR complex: potential diagnostics in first trimester pregnancy screening for stillbirth, down's syndrome, preterm delivery and preeclampsia.
Chambers AE, Griffin C, Naif SA, Mills I, Mills WE, Syngelaki A, Nicolaides KH, Banerjee S.
Reprod Biol Endocrinol 2012;10:113. -
Body Mass Index at 11-13 Weeks' Gestation and Pregnancy Complications.
Syngelaki A, Bredaki FE, Vaikousi E, Maiz N, Nicolaides KH.
Fetal Diagn Ther 2011;30:250-65. -
Screening for fetal aneuploidies at 11 to 13 weeks.
Nicolaides KH.
Prenat Diagn 2011;31:7-15. -
Pregenesys pre-eclampsia markers consensus meeting: What do we require from markers, risk assessment and model systems to tailor preventive strategies?
Cetin I, Huppertz B, Burton G, Cuckle H, Gonen R, Lapaire O, Mandia L, Nicolaides K, Redman C, Soothill P, Spencer K, Thilaganathan B, Williams D, Meiri H.
Placenta 2011;32:S4-16. -
Maternal serum alpha-fetoprotein in normal pregnancy at 11-13 weeks' gestation.
Bredaki FE, Wright D, Akolekar R, Cruz G, Nicolaides KH.
Fetal Diagn Ther 2011;30:274-9. -
Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11-13 weeks.
Beta J, Akolekar R, Ventura W, Syngelaki A, Nicolaides KH.
Prenat Diagn 2011;31:75-83. -
Maternal serum a-fetoprotein at 11-13 weeks' gestation in spontaneous early preterm delivery.
Beta J, Bredaki FE, Calvo JR, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2011;30:88-93. -
Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks.
Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH.
Prenat Diagn 2011;31:66-74. -
Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks.
Poon LC, Akolekar R, Lachmann R, Beta J, Nicolaides KH.
Ultrasound Obstet Gynecol 2010;35:662-70. -
First-trimester maternal plasma cell-free fetal DNA and preeclampsia.
Sifakis S, Zaravinos A, Maiz N, Spandidos DA, Nicolaides KH.
Am J Obstet Gynecol 2009;201:472.1-7. -
First trimester urinary placental growth factor and development of pre-eclampsia.
Savvidou M, Akolekar R, Zaragoza E, Poon L, Nicolaides K.
BJOG 2009;116:643-7. -
First-trimester prediction of hypertensive disorders in pregnancy.
Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH.
Hypertension 2009;53:812-8.